Gemcabene
- Generic Name
- Gemcabene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H30O5
- CAS Number
- 183293-82-5
- Unique Ingredient Identifier
- B96UX1DDKS
- Background
Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
- Indication
Investigated for use/treatment in atherosclerosis, cardiovascular disorders, and hyperlipidemia.
- Associated Conditions
- -
- Associated Therapies
- -
Gemcabene for the Treatment of Pediatric NAFLD
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Emory University
- Target Recruit Count
- 6
- Registration Number
- NCT03436420
- Locations
- ๐บ๐ธ
Children's Healthcare of Atlanta / Emory University, Atlanta, Georgia, United States
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
- Conditions
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT02944383
- Locations
- ๐บ๐ธ
Soma Medical Research, West Palm Beach, Florida, United States
๐บ๐ธUniversity of Maryland Medical Center, Baltimore, Maryland, United States
๐บ๐ธPhysicians East, NA, Greenville, North Carolina, United States
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02722408
- Locations
- ๐จ๐ฆ
Robarts Research Institute, London, Ontario, Canada
๐บ๐ธWestside Medical Associates of Los Angeles, Beverly Hills, California, United States
๐ฎ๐ฑWolfson Medical Center Internal Medicine Dept., Holon, Israel
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02634151
- Locations
- ๐บ๐ธ
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
๐บ๐ธAtlantic Clinical Research Collaborative- Cardiology, Atlantis, Florida, United States
๐บ๐ธProgressive Medical Research, Port Orange, Florida, United States
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 277
- Registration Number
- NCT02591836
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02571257
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.